赣南医学院学报2017，Vol.37Issue(1)：58-61,4.DOI:10.3969/j.issn.1001-5779.2017.01.015
FLAG方案治疗难治复发性急性白血病的临床疗效观察
Therapeutic effect of FLAG Regimen treating Patients with Refractory and Relapse Acute Leukemia
摘要
Abstract
Objective:To evaluate the clinical efficacy and adverse reaction of FLAG regimen in the treatment of patients with refractory and relapse acute leukemia.Methods:Forty-four patients with refractory and relapse acute leukemia in our hospital were treated with FLAG regimen, all patients were treated with symptomatic and supportive treatment during treatment period.Results:The complete remission(CR) rate after 1 course of induction therapy in patients with FLAG regimen was 36.4%, partial remission (PR) rate was 22.7% and the overall efficacy(OR) rate 59.1%;the OR rate of aged over and under 45 years old were 30% and 67.6%, WT1+-FLT3+-PRAME+ group and FLT3+-PRAME+ group were 54.5% and 50%,Refractory group and Relapse group were 55.6% and 64.7%.Conclusion:FLAG regimen has a significantly higher remission rate and an efficacy rate, adverse reactions caused by the regimen were bone marrow suppression and infection.Patients with refractory and relapse acute leukemia can tolerate this kind of adverse reactions, so it is commended using it in clinical practice, long-term efficacy needs to be further observed and followed up.关键词
氟达拉滨/阿糖胞苷/复发/难治/急性白血病Key words
Fludarabine/cytarabine/relapse/refractory/acute leukemia分类
医药卫生引用本文复制引用
辛柳燕,雎春芳,钟思思,刘爱飞,李方林,王金霞,陈懿建..FLAG方案治疗难治复发性急性白血病的临床疗效观察[J].赣南医学院学报,2017,37(1):58-61,4.基金项目
国家自然科学基金项目(81060047,81160073) （81060047,81160073）
江西省自然科学基金项目(20132BAB205053) （20132BAB205053）
江西省卫生厅重大项目基金项目(20114011) （20114011）
江西省教育厅科技落地计划(KJLD14085) （KJLD14085）
